Shionogi & Co Ltd
TSE:4507
Intrinsic Value
Shionogi & Co., Ltd. engages in the research, development, supply, manufacture, and sale of pharmaceutical products. [ Read More ]
The intrinsic value of one Shionogi & Co Ltd stock under the Base Case scenario is 596 937.04 JPY. Compared to the current market price of 7 114 JPY, Shionogi & Co Ltd is Undervalued by 99%.
Fundamental Analysis
Balance Sheet Decomposition
Shionogi & Co Ltd
| Current Assets | 757.2B |
| Cash & Short-Term Investments | 507.8B |
| Receivables | 154.4B |
| Other Current Assets | 95B |
| Non-Current Assets | 602.6B |
| Long-Term Investments | 295.3B |
| PP&E | 118.7B |
| Intangibles | 132B |
| Other Non-Current Assets | 56.7B |
| Current Liabilities | 115.3B |
| Accounts Payable | 12.7B |
| Other Current Liabilities | 102.6B |
| Non-Current Liabilities | 52.2B |
| Long-Term Debt | 6.6B |
| Other Non-Current Liabilities | 45.7B |
Earnings Waterfall
Shionogi & Co Ltd
|
Revenue
|
425.2B
JPY
|
|
Cost of Revenue
|
-60.1B
JPY
|
|
Gross Profit
|
365.1B
JPY
|
|
Operating Expenses
|
-223.8B
JPY
|
|
Operating Income
|
141.3B
JPY
|
|
Other Expenses
|
13.2B
JPY
|
|
Net Income
|
154.5B
JPY
|
Free Cash Flow Analysis
Shionogi & Co Ltd
What is Free Cash Flow?
Profitability Score
Profitability Due Diligence
Shionogi & Co Ltd's profitability score is 67/100. The higher the profitability score, the more profitable the company is.
Score
Shionogi & Co Ltd's profitability score is 67/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
Shionogi & Co Ltd's solvency score is 99/100. The higher the solvency score, the more solvent the company is.
Score
Shionogi & Co Ltd's solvency score is 99/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
Shionogi & Co Ltd
According to Wall Street analysts, the average 1-year price target for Shionogi & Co Ltd is 7 851.45 JPY with a low forecast of 5 454 JPY and a high forecast of 9 313.5 JPY.
Shareholder Return
Price
Shionogi & Co Ltd
| Average Annual Return | 4.98% |
| Standard Deviation of Annual Returns | 31.16% |
| Max Drawdown | -38% |
| Market Capitalization | 2T JPY |
| Shares Outstanding | 289 312 000 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Shionogi & Co., Ltd. engages in the research, development, supply, manufacture, and sale of pharmaceutical products. The company is headquartered in Osaka, Osaka-Fu and currently employs 5,485 full-time employees. The prescription drug business is engaged in the development of eight new drugs including hypercholesterolemia treatment drugs Crestor, antihypertensive drugs Ilbetan Family (Irbetan, Aimix, Iltra) and antidepressant drugs Sinbalta. The firm is engaged in the provision of information to contribute to medical care by maximizing its products. The over-the-counter (OTC) pharmaceutical business handles products tailored to customers' lifestyles. The in-vitro diagnostics business is engaged in the sale of products, as well as the provision of information on infectious diseases, cardiovascular diseases and allergic diseases. The firm mainly provides its products and services in Japan, Europe and North America markets.
You don't have any saved screeners yet
